Single answer
Is Aileron Therapeutics Inc (ALRN) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
No analyst target data available for this ticker.
Company snapshot
A quick overview of the business and its public profile.
Aileron Therapeutics Inc operates as a clinical stage chemoprotection oncology company in the United States The company is developing ALRN6924 which is in Phase 1 trial for solid tumor and lymphoma Phase 2a clinical trial to treat peripheral Tcell lymphoma Phase I clinical trial for the treatment of acute myeloid leukemia AML and advanced myelodysplastic syndrome MDS Phase 1b trial to test the combination of ALRN6924 and cytarabine or AraC in patients with MDS and a Phase 2a combination trial of ALRN6924 and palbociclib in patients with tumors harboring MDM2 amplifications coamplifications as well as for patients with p53mutated small cell lung cancer that has completed Phase 1b clinical trial It has a license agreement with DanaFarber Cancer Institute and Harvard College and Umicore Precious Metals Chemistry USA LLC The company was formerly known as Renegade Therapeutics Inc and changed its name to Aileron Therapeutics Inc in February 2007 Aileron Therapeutics Inc was incorporated in 2001 and is based in Boston Massachusetts
Website: httpswwwaileronrxcom
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: 0.00. Net profit margin: -46,734.10%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for Aileron Therapeutics Inc is $279,083. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
We cannot find data for Aileron Therapeutics Inc 10 years ago, but if you had invested on 2017-06-29 when the price was $216.00, you would have made a loss of $213.95 per share or 99.05%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.
No analyst target data available for this ticker.